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ABSTRACT 
 
At present, treatment for Parkinson’s disease (PD) is only symptomatic, therefore it is important 
to identify new targets tackling the molecular causes of the disease. We previously found that 
lymphoblasts from sporadic PD patients display increased activity of the cyclin D3/CDK6/pRb 
pathway and higher proliferation than control cells. These features were considered systemic 
manifestations of the disease, as aberrant activation of cell cycle is involved in neuronal 
apoptosis.  The main goal of this work was to elucidate whether the inhibition of cyclin 
D3/CDK6-associated kinase activity could be useful in PD treatment. For this purpose, we 
investigated the effects of two histone deacetylase (HDAC) inhibitors, suberoylanilide 
hydroxamic acid (SAHA) and sodium butyrate (NaB), and the m-TOR inhibitor rapamycin on 
cell viability and cyclin D3/CDK6 activity. Moreover, the potential neuroprotective action of 
these drugs was evaluated in 6-hydroxy-dopamine (6-OHDA) treated dopaminergic SH-SY5Y 
cells and primary rat mesencephalic cultures. Here we report that both compounds normalized 
the proliferative activity of PD lymphoblasts and reduced the 6-OHDA-induced cell death in 
neuronal cells by preventing the overactivation of the cyclin D3/CDK6/pRb cascade. 
Considering that these drugs are already used in clinic for treatment of other diseases with good 
tolerance, it is plausible that they may serve as novel therapeutic drugs for PD. 
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INTRODUCTION 
 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss 
of dopaminergic neurons in the substantia nigra of the mid-brain. The clinical characteristics of 
PD are disabling motor abnormalities, including tremor, muscle rigidity, paucity of voluntary 
movements, and postural instability (Jankovic 2008). Other non-motor features like mood 
disorders, sleep disturbances, and cognitive impairment are also associated to PD (Chaudhuri & 
Schapira 2009). Approximately 90% of cases of PD are considered sporadic, being the rest 
determined by gene mutations. It is believed that non-genetic factors could play an important 
role in sporadic PD, by interacting with susceptibility genes. Age is a major risk factor for 
idiopathic PD. The average age at onset is 60 years and disease duration is approximately 15 
years (Fan et al. 2013, Samii et al. 2004).  
Current treatment strategies for PD include symptomatic treatments that consist primarily on 
replacing dopamine in the brain with levodopa or dopamine agonists (Djamshidian et al. 2014, 
Pahwa & Lyons 2014). Nevertheless, the chronic dopamine replacement therapy can cause 
debilitating side effects as bradykinesia. Consequently, it is important to develop new 
neuroprotective strategies that can help to halt or slow the progression of PD. 
The cause of neuronal death in PD and other neurodegenerative disorders is largely unknown, 
but it appears that apoptosis is the final fate of vulnerable neurons in PD (Hajimohamadreza & 
Treherne 1997). Mounting evidence suggest that neuronal apoptosis is the result, at least in part, 
of dysregulation of cell cycle control in post-mitotic neurons (Copani et al. 2001). First of all, 
cell cycle-related proteins have been shown to be elevated in neurons that are at risk to die in 
various neurodegenerative disorders including PD (Jordan-Sciutto et al. 2003). Second, some 
cell cycle inhibitors appear to have neuroprotective properties in cell culture and animal models 
(Alvira et al. 2007, Park et al. 2000). 
Work carried out in the last decade in our laboratory demonstrated the existence of cell cycle 
disturbances in immortalized lymphocytes from Alzheimer’s disease (AD), frontotemporal 
lobar degeneration (FTLD) and PD (Alquezar et al. 2012, Bartolome et al. 2009, Esteras et al. 
2014). Lymphoblasts from sporadic PD were shown to have a higher proliferative activity than 
cells from control individuals associated with a cyclin D3/CDK6-dependent 
hyperphosphorylation of pRb (Esteras et al. 2014). Considering that CDKs and/or cyclins have 
been reported in a number of in vitro neuronal death paradigms (Katchanov et al. 2001, Osuga 
et al. 2000, Rashidian et al. 2005), we think that lymphoblasts, easily accessible cells, from 
sporadic PD patients could be a useful model to study cell cycle-related events in PD pathology, 
and a suitable platform to test the effects of drugs that have been proven to be useful in other 
diseases.  
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In particular, this work was undertaken to explore whether treatment with histone deacetylase 
(HDAC) inhibitors like sodium butyrate (NaB) or vorinostat, suberoylanilide hydroxamic acid 
(SAHA), which inhibit CDK6 expression levels, as well as the immunosuppressant rapamycin 
that downregulates cyclin D3 content, could normalize the proliferative response of PD 
lymphoblasts. Moreover, the potential neuroprotective action of these drugs was evaluated in 
well-established cell models for PD such as the 6-hydroxy-dopamine (6-OHDA)-treated 
dopaminergic SH-SY5Y cells and 6-OHDA-treated primary rat mesencephalic cultures. 
The results herein reported suggest that cyclin D3/CDK6 could be considered as a novel 
pharmacological target for PD, and that the repositioning of SAHA, NaB and rapamycin, drugs 
already licensed for different conditions, towards the treatment of PD could be a time- and cost-
saving strategy.  
 6 
 
MATERIALS AND METHODS 
 
Materials 
All components for cell culture were obtained from Invitrogen (Carlsbad, CA). L-DOPA, 6-
OHDA, the HDAC inhibitors, NaB and SAHA, and rapamycin were obtained from Sigma-
Aldrich. PVDF (polyvinylidene difluoride) Immobilon-P membranes for Western blots were 
purchased from Millipore. Rabbit anti-human antibodies, such as pRb (sc-50), CDK6 (sc-177), 
and mouse anti-human antibodies !-tubulin (sc-23948) and "-actin (sc-47778) were from Santa 
Cruz Biotechnologies.  Mouse anti-human Cyclin D3 was obtained from Cell Signaling. Mouse 
anti-human Lamin B was from Calbiochem. The enhanced chemiluminiscence (ECL) system 
was from Amersham. All other reagents were of molecular grade.  
Cell lines 
A total of 20 patients were diagnosed in the department of Neurology of the University Hospital 
Doce de Octubre (Madrid, Spain) of sporadic PD following Diagnostic Criteria published 
elsewhere (Gelb et al. 1999). All patients were undergoing treatment with levodopa, alone or in 
combination with dopamine agonists (13 cases), selegiline or rasagiline (2 cases). A group of 20 
age-matched individuals was used as control. The control group was formed of family members 
or caregivers of the PD patients, and showed a completely normal cognitive and functional 
level. Demographic characteristics of PD patients and control subjects are presented in Table 1. 
In all cases peripheral blood samples were obtained after written informed consent of the 
donors. All study protocols were approved by the Spanish Council of Higher Research 
Institutional Review Board and are in accordance with National and European Union 
Guidelines. Peripheral Blood Mononuclear Cells (PBMCs) were isolated on Lymphoprep™ 
density-gradient centrifugation according to the instructions of the manufacturer (Axix-Shield). 
Cells were washed twice with phosphate buffered saline (PBS), counted and resuspended at the 
desired concentration.  
Establishment of lymphoblastoid cell lines (LCLs) was performed in our laboratory as 
previously described (Ibarreta et al. 1997) by infecting PBMCs with the Epstein-Barr virus 
(EBV). Cells were grown in suspension in T flasks in an upright position, in approximately 10 
mL RPMI 1640 (Gibco, BRL) medium that contained 2 mM L-glutamine, 100 !g/mL 
penicillin/streptomycin and, unless otherwise stated, 10% (v/v) fetal bovine serum (FBS) and 
maintained in a humidified 5% CO2 incubator at 37 ºC. Fluid was routinely changed every 3 
days by removing the medium above the settled cells and replacing it with an equal volume of 
fresh medium. 
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Neuronal cell culture  
Human neuroblastoma (SH-SY5Y) cells were purchased from the European Collection 
of Cell Cultures (Health Protection Agency, Salisbury, UK), and were propagated in 
Dulbecco’s Modified Eagle Medium (DMEM) containing L-glutamine (2 mM), 1% 
nonessential amino acids, 1% penicillin/streptomycin and 10% fetal bovine serum (FBS) under 
humidified 5% CO2 and 95% air. On attaining semiconfluence, cells were treated with 6-
OHDA (35 µM) for 24 hours. Some cultures were pretreated for 1 hour with different 
compounds at several concentrations.  After treatment, cultures were processed for cell viability 
assay or Western blotting. 
Primary ventral mesencephalic cell culture 
Young (3-5 months) Wistar rats were obtained from the inbred colony of the Research Institute, 
Hospital Doce de Octubre, Madrid, Spain. Primary mesencephalic cultures were prepared from 
rat embryos (E15-16) according to methods described previously with some modification (Yin 
et al. 2012, Pruszak et al. 2009). 1 x 105 cells were plated in pretreated poly-D-lysine-coated 
96-well plates. Cells were maintained at 37ºC in a 5% CO2 humidified atmosphere in 
Neurobasal A medium (Gibco) that contained 2 mM L-glutamine, and 10% B27® Supplement 
(Invitrogen). 9 days after cell culture preparation, mesenchephalic cells were treated with 35 µM 
of 6-OHDA for 24 hours and pretreated or not for 1 hour with increasing concentrations of 
SAHA, NaB and rapamycin.  After treatment, cultures were processed for cell viability assay 
(MTT). All animals were handled and cared for Council Directive 2010/63/UE of September 
22, 2010. 
Measurement of cell proliferation, cell viability and cell cycle 
Cell proliferation was determined by total cell counting, using a TC10™ Automated Cell 
Counter (Bio-Rad Laboratories, Madrid, Spain). Cells failing to exclude the dye were 
considered nonviable.  Cell viability was determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay, as previously described (Denizot & Lang 1986). Cell 
survival was estimated as the percentage of the value of untreated controls. Cell cycle phase 
distribution was routinely determined by cell permeabilization followed by propidium iodide 
(PI) staining and flow cytometry analysis using an EPICS-XL cytofluorimeter (Coulter 
Científica, Móstoles, Spain). 
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Immunoblotting analysis 
Whole-cell extract preparation, SDS-PAGE and Western blot analysis of lymphoblasts or 
neuroblastoma cells were performed as described in previous publications (Alquezar et al. 2012, 
Esteras et al. 2014).  Primary antibodies were used at the following dilutions: 1:500 anti-pRb, 
1:500 anti-cyclin D3, 1:1000 anti-CDK6, 1:1000 anti-"-actin, 1:1000 anti-!-tubulin, 1:1000 
anti-Lamin B. Protein band densities were quantified using Image J software (NIH, Bethesda, 
Maryland, USA) after scanning the images with a GS-800 densitometer from BioRad.  
Quantitative Real-Time PCR 
Total RNA was extracted from cell cultures using Trizol™ reagent (Invitrogen). RNA yields 
were quantified spectrophotometrically and RNA quality was checked by the A260/A280 ratio 
and on a 1.2% agarose gel to observe the integrity of 18S and 28S rRNA. RNA was then treated 
with DNase I Amplification Grade (Invitrogen). One microgram was reverse transcribed with 
the Superscript III Reverse Transcriptase kit (Invitrogen). Quantitative real-time PCR was 
performed in triplicates using TaqMan™ Universal PCR MasterMix No Amperase UNG 
(Applied Biosystems) reagent according to the manufacturer’s protocol. Primers were designed 
using the Universal Probe Library for Human (Roche Applied Science) and used at a final 
concentration of 20 µM. The sequences of the forward and reverse primers used are 5’-
tgatcaactaggaaaaatcttggac-3’ and 5’-ggcaacatctctaggccagt-3’ for CDK6 and 5’-
ccaaccgcgagaagatga-3’ and 5’-ccagaggcgtacagggatag-3’ for "-actin. 
Real time quantitative PCR was performed in the Bio-Rad iQ5 system using a thermal profile of 
an initial 5-min melting step at 95ºC followed by 40 cycles at 95ºC for 10s and 60ºC for 60s. 
Relative mRNA levels of the genes of interest were normalized to "-actin expression using the 
simplified comparative threshold cycle delta CT method [2 ("CT CDK6-"CT !-actin].  
Statistics 
Statistical significance was determined by the Student’s t-test or two-way analysis of variance 
(ANOVA) followed by Bonferroni’s test for multiple comparisons using GraphPad Prism 6 for 
Macintosh (La Jolla, CA, USA). A value of p<0.05 was considered significant. All the 
statistical data are presented as mean ± standard error of the mean (SEM).  
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RESULTS 
Proliferative activity of control and PD lymphoblasts 
Data in Fig. 1A shows proliferation of all cell lines derived from PD patients and age-matched 
control individuals used in this study. For these experiments, cells were seeded at an initial 
density of 1 x 106 cells x mL-1 in presence of 10% FBS and counted 72 hours after serum 
stimulation. In agreement with previous reports (Esteras et al. 2014), lymphoblasts from PD 
patients, showed higher rates of cell proliferation than those of control cells. To rule out an 
adverse effect of levodopa treatment to PD patients that could persist the immortalization 
procedure, we incubated a small number of lymphoblastoid cell lines from control and PD 
patients with L-DOPA. As shown in Fig. 1B, L-DOPA had no effect on proliferation of control 
and PD cells. As the enhanced proliferative activity of PD lymphoblasts was associated to the 
cyclin D3/CDK6-induced phosphorylation of the retinoblastoma protein (pRb) (Esteras et al. 
2014), we also investigated the effect of L-DOPA addition in the cellular levels of these 
proteins. Fig. 1C shows, as expected, increased levels of phosphorylated pRb, CDK6, and 
cyclin D3 proteins of PD lymphoblasts. In addition it is shown that L-DOPA did not modify the 
cellular content of these proteins.  
Effects of histone deacetylase inhibitors and rapamycin on cell proliferation of control and 
PD lymphoblasts 
Bearing in mind that CDK6 has shown to be epigenetically regulated by histone deacetylases 
(HDAC) (Kim et al. 2007, Giessrigl et al. 2013), we considered interesting to evaluate the 
effects of two different HDAC inhibitors, sodium butyrate (NaB) and suberoylanilide 
hydroxamic acid (SAHA) on the cell response to serum stimulation. SAHA is a US Food and 
Drug Administration-approved drug for the treatment of cutaneous T-Lymphoma (Slingerland 
et al. 2014) and NaB is being evaluated in clinical trials for the treatment of shigellosis (Raqib 
et al. 2012) and it is thought that could be effective on the treatment of colorectal cancer 
(Goncalves & Martel 2013). In addition and since degradation of cyclin D3 seems to be 
impaired in PD lymphoblasts (Esteras et al. 2014),  we investigated the influence of rapamycin, 
a US Food and Drug Administration-approved drug used as immunosuppressant (McAlister et 
al. 2002), in the proliferative response of control and PD lymphoblasts. Rapamycin was shown 
to downregulate cyclin D3 levels by increasing its degradation in the ubiquitin proteasome 
system (UPS) (Hleb et al. 2004).  
To investigate the effects of these drugs on cell proliferation, lymphoblasts were incubated in 
the absence or in the presence of SAHA, NaB or rapamycin for 72 hours and cell viability was 
determined by the MTT assay. Treatment with escalating concentrations (0-2 !M) of SAHA 
reduced the cell viability in a dose-dependent manner (Fig. 2A left panel). Similar results were 
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obtained with increasing concentrations of NaB up to 50 !M (Fig. 2B left panel) or with 
increasing concentrations of rapamycin (Fig. 2C, left panel). Maximal effects of SAHA, NaB 
and rapamycin were obtained at 1 !M, 10 !M, and 30 ng/mL respectively.  The proliferative 
activity of control and PD lymphoblasts was further assessed by total cell counting after treating 
cells with SAHA, NaB, or rapamycin for 72 hours. As shown in Fig. 2A-C right panels, the 
addition of SAHA (1 !M), NaB (10 !M) or rapamycin (30 ng/mL) abrogated the enhanced 
proliferative response of cells from PD patients, affecting in a lesser extent the proliferation of 
control cells.   
Effects of SAHA, NaB and rapamycin on cell cycle status of control and PD lymphoblasts 
Since the change in cell number depends on the balance between cell proliferation and cell 
death, we tested if SAHA, NaB or rapamycin treatment induced cell death by necrosis/apoptosis 
or by contrast, were able to decrease the enhanced cell proliferation observed in PD 
lymphoblasts. For this purpose, lymphoblasts from control and PD individuals were stained 
with propidium iodide (PI) and the distribution of cells in the cell cycle phases was analyzed by 
flow cytometry. We did not observe significant changes in the proportion of sub-G0/G1 
hypodiploid cells, characteristic of apoptosis/necrosis, in control and PD lymphoblasts after 
SAHA, NaB or rapamycin treatment (Fig. 3). SAHA was more effective in decreasing the 
percentage of cells in S/G2M phases than the other HDAC inhibitor NaB. Taken together, these 
results suggest that the decreased cell number in cultures of PD lymphoblasts in the presence of 
all the drugs used in this work truly reflects a decrease in cell proliferation.  
Effects of SAHA, NaB and rapamycin on cyclin D3/CDK6 levels and associated kinase 
activity  
We next evaluated the impact of SAHA, NaB and rapamycin treatment on the levels of cyclin 
D3 and CDK6 proteins and in their associated kinase activity, assessed indirectly by the 
phosphorylation status of pRb, as well as in the levels of CDK6 mRNA. In agreement with our 
previous work (Esteras et al. 2014), we found that the relative CDK6 mRNA levels were 
elevated in PD cells compared with those of control cells (Fig. 4A). As expected, both HDAC 
inhibitors were able to blunt the increase in CDK6 expression. At the dose used (1 µM SAHA or 
10 µM NaB), they had no effect in CDK6 mRNA levels in control cells (Fig. 4A). In 
consonance with these results, Fig. 4B shows that these compounds were effective in restoring 
the normal levels of CDK6 protein and in preventing the increased phosphorylation of pRb in 
PD lymphoblasts. The effect of 30 ng/mL of rapamycin in decreasing the levels of cyclin D3 in 
control and PD lymphoblasts is shown in Fig. 4C (left panel). Consequently, the addition of 
rapamycin partially prevented the higher phosphorylation of the pRb protein in lymphoblasts 
derived from PD patients (Fig. 4C right panel). 
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Neuroprotective effect of SAHA, NaB and rapamycin on 6-OHDA-induced death in 
neuroblastoma SH-SY5Y cells and dopaminergic primary cultures 
We considered interesting to validate the above-described results in lymphoblastoid cell lines by 
testing the effects of cyclin D3/CDK6 kinase activity-modifying drugs in two well-established 
neuronal models of PD, neuroblastoma SH-SY5Y cells (Ouyang & Shen 2006) and primary 
cultures of dopaminergic mid-brain cells (Pruszak et al. 2009). To this end, cells were pretreated 
for 1 hour with SAHA, NaB, or rapamycin before 6-OHDA (35 µM) exposure. Fig. 5 
summarizes the effects of these drugs on 6-OHDA-treated SH-SY5Y neuroblastoma cells at the 
same dose used in the experiments with lymphoblasts.  Fig. 5A shows that, as expected, the 
addition of 6-OHDA to the SH-SY5Y cells resulted in significant cell death (50%). The pre-
treatment of these cells with the HDAC inhibitors or rapamycin partially prevented the cell 
death induced by the toxin 6-OHDA. To elucidate whether changes in cyclin D3/CDK6 activity 
are involved in the cell death induced by this neurotoxin, we determined the levels of both 
CDK6 and cyclin D3 as well as the phosphorylation status of the pRb protein in the absence and 
in the presence of SAHA, NaB and rapamycin. 6-OHDA induced significant increases in CDK6 
and cyclin D3 proteins (Fig. 5B) and therefore in the phosphorylated form of the pRb protein 
(Fig. 5C). The pretreatment with SAHA, NaB or rapamycin limited the increase in these 
proteins caused by the addition of 6-OHDA, suggesting the involvement of cyclin D3/CDK6 in 
neuronal survival. 
Finally, we sought to evaluate the potential neuroprotective role of these drugs in non-dividing, 
post-mitotic neurons as primary rat mesencephalic neuronal cultures. To this end, cells were 
pretreated with escalating concentrations of SAHA (0-2 !M), NaB (0- 50 !M) or rapamycin (0-
100 ng/mL) for 1 hour before 6-OHDA (35 µM) exposure, and cell viability was analyzed 24 
hours later by MTT assay. Fig. 6 shows that the addition of 6-OHDA to the mesencephalic cells 
resulted in a significant cell death (40%). The pre-treatment of these cells with increasing 
concentrations of HDAC inhibitors (Fig. 6A) or rapamycin (Fig. 6B) partially prevented the cell 
death induced by the toxin 6-OHDA. 
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DISCUSSION 
 
In this work, we have evaluated the effects of targeting cyclin D3/CDK6 activity on 
survival/death in cellular models of PD, particularly immortalized lymphocytes from sporadic 
PD patients, human dopaminergic SH-SY5Y neuroblastoma cells, and primary rat mid-brain 
cell cultures treated with 6-OHDA.  
The use of peripheral cells form patients as surrogate tissue for allowing early diagnosis and 
more efficacious treatment for neurodegenerative disorders is widely accepted. Assuming that 
biomolecular defects associated with PD could be detected in any cell type, numerous studies 
have been carried out using peripheral cells isolated from blood (i.e. lymphocytes, monocytes, 
platelets, red blood cells) of PD patients (Irrcher et al. 2010, Saito et al. 2009, Zhong et al. 
2006, Jakubauskiene et al. 2012). Moreover PBMCs can synthesize endogenous dopamine and 
express DA receptors (DA-Rs) and DA transporters (McKenna et al. 2002). Lymphoblastoid 
cell lines from patients can be easily obtained by infecting PBMCs with EBV. They resemble 
activated B cells in the expression of activation markers and adhesion molecules (Wang et al. 
1990). Previous works from our laboratory demonstrated that EBV-immortalized lymphocytes 
respond to serum addition or withdrawal as fresh isolated lymphocytes do, and display similar 
changes in the content of certain proteins implicated in the regulation of proliferation and 
survival (Bartolome et al. 2009, Munoz et al. 2008). Taken together, these findings support the 
use of these lymphoblastoid cell lines for the study of disease and therapy-related modifications 
within ex vivo non-neural DA cells of individuals with PD. On the other hand, the human 
dopaminergic SH-SY5Y cell line and primary cultures of rat mid-brain neurons exposed to 6-
OHDA are used commonly as in vitro models for PD, as it reflects cellular processes that occur 
in the degenerating dopaminergic neurons (Ouyang & Shen 2006, Kim et al. 2010).  
Here, we confirmed previous data from our laboratory (Esteras et al. 2014) indicating a higher 
rate of proliferation of PD lymphoblasts than cells from age-matched control individuals, that 
was associated with increased cyclin D3/CDK6-mediated phosphorylation of the pRb protein. 
Activation of the pRb pathway has been reported in PD brain and in mouse models of PD 
(Hoglinger et al. 2007) although in neurons this leads to cell death rather than to cell division. 
Thus, our results support the hypothesis that unscheduled cell cycle activation underlies 
neurodegeneration.  
Since positive regulation of CDK6 expression is achieved by HDACs (Dhar et al. 2014) and 
considering that inhibitors of HDACs have been theorized to be as efficacious in 
neurodegenerative diseases as in cancer (Harrison & Dexter 2013), we investigated whether two 
different HDAC inhibitors, SAHA and NaB, which are known to cross the blood brain barrier 
(BBB) (Barichello et al. 2014, Palmieri et al. 2009) could normalize the cell response of PD 
lymphoblasts. Although SAHA and NaB differ in their chemical structure (hydroxamate, or 
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short chain fatty acid), they both inhibited the Zn-dependent HDACs, mainly of the class I and 
II.  SAHA and NaB were effective in decreasing the serum-mediated increase of CDK6 levels 
and restored the normal rate of cell proliferation in PD lymphoblasts.  These results are in line 
with a previous report indicating that these two broad classes of HDAC inhibitors (I and II) 
decreased proliferation of neural stem cells by blocking G1/S transition (Zhou et al. 2011), as 
well as in other normal or transformed cells (Riester et al. 2007). The concentration of SAHA (1 
!M) falls within the range of the peak serum concentration achieved in patients treated with 
effective oral anti-tumor doses of this compound (Kelly et al. 2005).  Moreover, the fact that 
SAHA was shown to induce changes in inflammatory markers in a mouse model of septic shock 
(Finkelstein et al. 2010) suggest that SAHA may have secondary beneficial effects in PD 
besides normalizing CDK6 levels. On the other hand, NaB has been reported to reduce 
degeneration of dopaminergic neurons in a mutant alpha-synuclein drosophila transgenic model 
of familial PD (Kontopoulos et al. 2006) and to rescue the rotenone-induced locomotor 
impairment and early mortality in flies (St Laurent et al. 2013), suggesting a possible benefit in 
the early step of PD. 
Rapamycin or sirolimus is widely used to prevent transplant rejection, due to its good efficacy 
and reduced toxicity (Morath et al. 2007). Moreover, rapamycin has been shown to effectively 
inhibit the growth of several murine and human cancer (Vignot et al. 2005). The capacity of 
rapamycin to stimulate autophagy makes this dug attractive for neurodegenerative disorders 
associated with impaired organelle and protein turnover (Pignataro et al. 2011). Our results 
show an antiproliferative effect of rapamycin in PD lymphoblasts, which can be explained by 
the effects of rapamycin restoring both the increased cyclin D3 levels and its associated kinase 
activity.  
Although PD-associated changes detected in peripheral cells from patients might not fully 
reflect those of PD brain, it is worth to mention that at the doses used in this work, NaB, SAHA 
and rapamycin were able to partially prevent the cell death induced by 6-OHDA in neuronal 
models of PD, as the human neuroblastoma SH-SY5Y cell line or primary rat mid-brain 
dopaminergic neuronal cultures.  These results are in agreement with previous work reporting 
the effects of this neurotoxin in pRb phosphorylation (Rodriguez-Blanco et al. 2008), and add 
further support to the hypothesis that cell cycle alterations underlie neuronal loss.  Taking 
together it seems that lymphoblasts from PD patients can be considered as a useful experimental 
model to study molecular events associated with the disease, as well as an interesting platform 
for testing novel therapies.  
In conclusion, our data indicate that increased proliferation of PD lymphoblasts is causally 
linked to overactivation of cyclin D3/CDK6 complex, and that treatments aimed at blocking 
cyclin D3/CDK6-associated kinase activity are effective in decreasing the enhanced cell 
proliferation of PD lymphoblasts. The proposed scenario is represented schematically in Figure 
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7. NaB and SAHA, by inhibiting CDK6 protein expression, or rapamycin by decreasing the 
cellular levels of cyclin D3, are able to rescue the normal rates of proliferation of PD 
lymphoblasts. 
Considering that the HDAC inhibitors as well as rapamycin are already drugs used for the 
treatment of several diseases with a good tolerance it seems reasonable to believe that they may 
hold promise as a novel treatment for PD. The repositioning of these known drugs towards PD 
may be therefore a time and cost-saving strategy. 
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TABLE 1. 
Demographic characteristics of PD patients and healthy subjects  
 
 Control Parkinson’s Disease 
Number 20 20 
Gender (M/F) 
Age study 
4/16 
63.0 ± 2.8 
16/4 
69.2 ± 2.2 
Age onset NA 64.5 ± 2.2 
Hoehn and Yahr scale 
UPDRS 
NA 
NA 
2.3 ± 0.2 
24.8 ± 1.6 
Levodopa dosage (mg/24hours) NA 603.3 ± 62.7 
Values are expressed as mean ± SEM. NA not applied 
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FIGURE LEGENDS 
 
 
Figure 1 
Proliferation of lymphoblasts from control and PD patients 
Control and PD lymphoblasts were seeded at an initial density of 1 x 106 cells x mL-1 and 
synchronized by serum starvation for 24 hours. On that point, 10% FBS was added alone (A) or 
in combination with L-DOPA (100 µM) (B) and 72 hours later samples were taken and counted 
using a TC10TM Automated Cell Counter from BioRad. C. For Western blot analysis, cells were 
harvested 24 hours after L-DOPA addition and whole-cell lysates were prepared to analyze the 
levels of pRb, CDK6, and cyclin D3 proteins. Representative immunoblots are shown. pp = the 
hyperphosphorylated form of the pRb protein. Values shown!represent the mean ± SEM of the 
quantification of the corresponding band in six independent observations carried out with 
different cell lines. (* p<0.05 and **p<0.01 significantly different from control cells). 
 
Figure 2 
Effects of HDAC inhibitors and rapamycin on the proliferation of lymphoblasts from 
control and PD patients 
Immortalized lymphocytes from control and PD patients, were seeded at an initial density of 1 x 
106 x mL-1 and were incubated in medium containing 10% FBS, in the absence or in presence of 
increasing doses of SAHA (0-2 µM) (A left panel), NaB (0-50 µM) (B left panel) and 
rapamycin (0-100 ng/mL) (C left panel) for 72 hours. A total of 100,000 cells per well were 
seeded in a 96-well plaque for the MTT assay. Results represent the % of cell proliferation of 
treated cells referred to untreated ones. A, B, and C right panels. Effect of the treatment with 
SAHA (1 µM), NaB (10 µM), or rapamycin (30 ng/mL) on proliferation of control and PD 
lymphoblasts. Aliquots were taken for cell counting 72 hours after the drug administration. Data 
shown are the mean ± SEM of ten determinations for each drug carried out with different cell 
lines (* p<0.05 and **p<0.01 significantly different from control cells. †p<0.05 and ††p<0.01 
significantly different from untreated cells). 
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Figure 3 
Cell cycle distribution of lymphoblasts from control and PD patients after treatment with 
HDAC inhibitors or rapamycin 
Immortalized lymphocytes from control and PD patients were seeded at an initial density of 1 x 
106 x mL-1 and cultured in RPMI medium containing 10% FBS in the absence or in the presence 
of the HDAC inhibitors SAHA (1 µM) and NaB (10 µM) or rapamycin (30 ng/mL). 24 hours 
after drugs addition, cells were harvested, fixed, and analyzed by flow cytometry as described 
under Methods.  The percentage of cells in the different cell cycle phases is indicated for each 
condition. 
 
Figure 4 
Effects of SAHA, NaB and rapamycin on cyclin D3/CDK6 levels and pRb phosphorylation 
status 
Immortalized lymphocytes from control and PD patients were seeded at an initial density of 1 x 
106 x mL-1, and were incubated in RPMI medium containing 10% FBS in the absence or in the 
presence of SAHA (1 µM), NaB (10 µM) or rapamycin (30 ng/mL). 24 hours after treatment 
cells were harvested to analyze CDK6 mRNA expression by quantitative RT-PCR or the levels 
of cyclin D3, CDK6 and pRb proteins by Western blotting. A. CDK6 mRNA expression levels 
after SAHA and NaB treatment. Data shown represent the mean ± SEM of different 
experiments carried out with five control and five PD patients. B and C. Representative 
immunoblots showing the effect of SAHA and NaB on CDK6 and pRb proteins or the effect of 
rapamycin on cyclin D3 levels and pRb phosphorylation status. pp = the hyperphosphorylated 
form of the pRb protein. The densitometric data represent the mean ± SEM of different 
experiments using all the individuals enrolled in this study (*p<0.05 and **p<0.01 significantly 
different from control cells; †p<0.05 and ††p<0.01 significantly different from untreated cells). 
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Figure 5 
Effects of HDAC inhibitors and rapamycin on survival and protein levels of pre-treated 6-
OHDA SH-SY5Y neuroblastoma cells. 
Neuroblastoma SH-SY5Y cells were exposed to 35 µM 6-OHDA for 24 hours in the presence 
or in the absence of HDAC inhibitors (1 µM for SAHA and 10 µM for NaB) or rapamycin (30 
ng/mL). A. Number of viable cells after drug treatments measured by MTT assay.  Each data 
point represents the mean ± SEM of three replications in four different experiments. (**p< 0.01 
significantly different from SH-SY5Y untreated cells; †p<0.05 and ††p<0.01 significantly 
different from 6-OHDA-treated cells). B and C. CDK6, cyclin D3 and pRb protein levels 
assessed by Western blotting. Representative immunoblots are shown. The densitometric data 
represent the mean ± SEM of four different experiments (*p<0.05 and **p<0.01 significantly 
different from SH-SY5Y untreated cells; †p<0.05 and ††p<0.01 significantly different from 6-
OHDA-treated cells). pp = the hyperphosphorylated form of the pRb protein. 
 
 
Figure 6 
Neuroprotective effects of HDAC inhibitors and rapamycin in 6-OHDA pre-treated 
mesencephalic primary cultures 
A and B. Primary cultures of rat mid-brain cells were exposed to 35 µM 6-OHDA for 24 hours 
in the presence or in the absence of different concentrations of HDAC inhibitors (0-2 µM for 
SAHA and 0-50 µM for NaB) (A) or rapamycin (0-100 ng/mL) (B).  The number of viable cells 
was measured by MTT assay.  Each data point represents the mean ± SEM of four replications 
in four different experiments. (**p< 0.01 significantly different from untreated cells; †p<0.05 
and ††p<0.01 significantly different from 6-OHDA-treated cells). 
 
Figure 7 
Diagram summarizing the effects of targeting the cyclin D3/CDK6 complex in the 
proliferative activity of Parkinson’s disease lymphoblasts 
Lymphoblasts from PD patients show an overactivation of the cyclin D3/CDK6-associated 
kinase activity compared with that of control cells. Treatment of PD cells with the HDAC 
inhibitors NaB and SAHA or targeting the cyclin D3 degradation by rapamycin normalized the 
cellular content of the cyclin D3/CDK6 complex, and restored normal rates of cell proliferation.  
!







